Citri to activate sales of anti-fungal drug, Terbinafine,

Published: 2003-06-12 07:10:00

Updated: 2003-06-12 07:10:00

Citri (President: Kim Wan-joo) is now launching Terbinafine, an anti-fungal tablet, into the market under the co-marketing agreement with Goodmorning Pharm. Co. on May 30, mainly targeting hospitals and private clinics starting from June 1.

They estimated the total world market potentiality of Terbinex tablet (Terbinafine) at U$700 million.

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.